Order Article Reprints

Hooper J, Paolino KM, Mills K, Kwilas S, Josleyn M, Cohen M, Somerville B, Wisniewski M, Norris S, Hill B, et al. A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation. Vaccines. 2020; 8(3):377. https://doi.org/10.3390/vaccines8030377

Hooper, Jay, K. M. Paolino, K. Mills, S. Kwilas, M. Josleyn, M. Cohen, B. Somerville, M. Wisniewski, S. Norris, B. Hill, and et al. 2020. "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" Vaccines 8, no. 3: 377. https://doi.org/10.3390/vaccines8030377

Hooper, J., Paolino, K. M., Mills, K., Kwilas, S., Josleyn, M., Cohen, M., Somerville, B., Wisniewski, M., Norris, S., Hill, B., Sanchez-Lockhart, M., Hannaman, D., & Schmaljohn, C. S. (2020). A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation. Vaccines, 8(3), 377. https://doi.org/10.3390/vaccines8030377